MedTrace Logo

ORTHOVISC Shoulder Osteoarthritis Study

NCT00436969 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 274

Last updated 2017-03-09

Study results available
· View outcomes & findings →

Summary

A comparison of Orthovisc to corticosteroid injections in the shoulder for pain due to osteoarthritis.

Conditions

  • Glenohumeral Osteoarthritis

Interventions

DEVICE

Orthovisc

Orthovisc injection

DRUG

Control

Celestone (betamethasone sodium phosphate and acetate) - 2 mL

Sponsors & Collaborators

  • DePuy Mitek

    lead INDUSTRY

Principal Investigators

  • Jonathan B. McGlohorn · DePuy Synthes Mitek and Biomaterials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-02-28
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00436969 on ClinicalTrials.gov